Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01714687 · ClinicalTrials.gov registry record · NA
Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)
A NA study of Recurrent Acute Rhinosinusitis, sponsored by Integra LifeSciences Corporation.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
- 5
- Study locations
NCT01714687 is a NA study of Recurrent Acute Rhinosinusitis that has completed, run by Integra LifeSciences Corporation. The registered enrollment target is 59 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT01714687, a NA study of Recurrent Acute Rhinosinusitis, has completed, sponsored by Integra LifeSciences Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
- 5
- Study locations
Study Summary
This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
Conditions Studied
Interventions
- DEVICE balloon sinus dilation
- OTHER medical therapy
Study Locations (5)
Texas
- - Dallas
- - McKinney
Alabama
- - Birmingham
Georgia
- - Atlanta
Nevada
- - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2012-10-01 |
| Est. Completion | 2016-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01714687
The ClinicalTrials.gov registry entry for NCT01714687 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Acute Rhinosinusitis appearing as the primary indexed condition, and to 2 interventions - of which balloon sinus dilation is the first listed.
NCT01714687 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT01714687 about?
NCT01714687 is a clinical study titled "Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)". This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
What is the current status of trial NCT01714687?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2012-10-01. Estimated completion is 2016-04-01.
What conditions does trial NCT01714687 study?
This clinical trial studies the following conditions: Recurrent Acute Rhinosinusitis.
What interventions are being tested in trial NCT01714687?
The interventions under investigation include: balloon sinus dilation (DEVICE), medical therapy (OTHER).
Who is sponsoring clinical trial NCT01714687?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01714687 being conducted?
This trial has 5 study locations across Alabama, Georgia, Nevada, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.